Safety, efficacy and dosing questions linger for Lilly's Alzheimer's drug ahead of Monday adcomm

Ryan Cross

Senior Science Correspondent

The FDA detailed its biggest concerns about Eli Lilly’s experimental Alzheimer’s therapy donanemab ahead of a last-minute advisory committee meeting to convene Monday about the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Safety, efficacy and dosing questions linger for Lilly's Alzheimer's drug ahead of Monday adcomm

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

Eisai takes over development of ADC after Bristol Myers ends $650M collaboration

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Artiva refiles for IPO three years after original plans in a vastly different environment

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Safe­ty, ef­fi­ca­cy and dos­ing ques­tions linger for Lil­ly's Alzheimer's drug ahead of Mon­day ad­comm

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

Ei­sai takes over de­vel­op­ment of ADC af­ter Bris­tol My­ers ends $650M col­lab­o­ra­tion

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Arti­va re­files for IPO three years af­ter orig­i­nal plans in a vast­ly dif­fer­ent en­vi­ron­ment

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Safety, efficacy and dosing questions linger for Lilly's Alzheimer's drug ahead of Monday adcomm

Why the Supreme Court's overrule of Chevron has major implications for the FDA

Eisai takes over development of ADC after Bristol Myers ends $650M collaboration

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Artiva refiles for IPO three years after original plans in a vastly different environment

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required